Kaio Maciel de Santiago-Silva

Kaio Maciel de Santiago-Silva

Auto-generated profile, based on publicly available information

Kaio Maciel de Santiago-Silva

Laboratório de Síntese de Moléculas Medicinais (LaSMMed), Departamento de Química, Centro de Ciências Exatas, Universidade Estadual de Londrina, Londrina, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
BBBruna Taciane da Silva Bortoleti
Bruna Taciane da Silva Bortoleti
LOLaudicea Nascimento Oliveira
Laudicea Nascimento Oliveira
FMFernanda Lima De Azevedo Maia
Fernanda Lima De Azevedo Maia
JCJoyce Cristina Castro
Joyce Cristina Castro
Raoni Schroeder B. GonçalvesRaoni Schroeder B. Gonçalves
Raoni Schroeder B. Gonçalves
Leishmaniasis is a neglected tropical disease caused by Leishmania species. Available therapeutic options have several limitations. The drive to develop new, more potent, and selective antileishmanial agents is thus a major goal. Herein we report the synthesis and the biological activity evaluation against promastigote and amastigote forms of Leishmania amazonensis of nine 4,8-dimethoxynaphthalenyl chalcones. Compound ((E)-1-(4,8-dimethoxynaphthalen-1-yl)-3-(4-nitrophenyl)prop-2-en-1-one), 4f, was the most promising with an IC50 = 3.3 ± 0.34 μM (promastigotes), a low cytotoxicity profile (CC50 = 372.9 ± 0.04 μM), and a high selectivity index (SI = 112.6). Furthermore, 4f induced several morphological and ultrastructural changes in the free promastigote forms, loss of plasma membrane integrity, and increased reactive oxygen species (ROS). An in silico analysis of drug-likeness and ADME parameters suggested high oral bioavailability and intestinal absorption. Compound 4f reduced the number of infected macrophages and the number of amastigotes per macrophage, with an IC50 value of 18.5 ± 1.19 μM. Molecular docking studies with targets, ARG and TR, showed that compound 4f had more hydrogen bond interactions with the ARG enzyme, indicating a more stable protein-ligand binding. These results suggest that 4,8-dimethoxynaphthalenyl chalcones are worthy of further study as potential antileishmanial drugs.

1 May 2023 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MFMarciéli Fabris
Marciéli Fabris
MSMariana Luiza Silva
Mariana Luiza Silva
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
PCPriscila Goes Camargo
Priscila Goes Camargo
CYP1B1 plays an essential role in cancer's pathogenesis since it activates procarcinogens. Significantly, this enzyme catalyzes the hydroxylation of 17β-estradiol, leading to carcinogenic metabolites involved in carcinogenesis and cancer progression. Therefore, the inhibition of CYP1B1 activity is considered a therapeutic target for chemotherapy. In addition, CYP1B1 is overexpressed in hormone-dependent cancer cells and could be related to resistance to anticancer drugs. However, the activity of CYP1B1 in the tumor microenvironment can metabolize and activate prodrugs in cancer cells, providing more selectivity and being useful for chemoprevention or chemotherapy strategies. Furthermore, due to its importance in anticancer drug design, recent studies have reported using computational methods to understand the intermolecular interactions between possible ligands and CYP1B1. Therefore, in this perspective, we highlight recent findings in developing CYP1B1 inhibitors (flavonoids, trans-stilbenes, estradiol derivatives, and carbazoles) and CYP1B1-activated prodrugs (a chalcone DMU-135 and an oxime DMAKO-20). Finally, we have analyzed their possible molecular interactions with this enzymatic target by molecular docking, which can help to design new active substances.

6 August 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
BBBruna Taciane da Silva Bortoleti
Bruna Taciane da Silva Bortoleti
TBTiago de Oliveira Brito
Tiago de Oliveira Brito
ICIvete Conchon Costa
Ivete Conchon Costa
CLCamilo Lima
Camilo Lima
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
In this report, we describe the synthesis and evaluation of nine N1,N2-disubstituted-benzoylguanidines against promastigotes and amastigotes forms of Leishmania amazonensis. The derivatives 2g and 2i showed low IC50 values against promastigote form (90.8 ± 0.05 µM and 68.4 ± 0.03 µM, respectively), low cytotoxicity profile (CC50 396 ± 0.02 µM and 857.9 ± 0.06 µM) for peritoneal macrophages cells and SI of 5.5 and 12.5, respectively. Investigations about the mechanism of action of 2g and 2i showed that both compounds cause mitochondrial depolarization, increase in ROS levels, and generation of autophagic vacuoles on free promastigotes forms. These compounds were also capable of reducing the number of infected macrophages with amastigotes forms (59.5% ± 0.08% and 98.1% ± 0.46%) and the number of amastigotes/macrophages (79.80% ± 0.05% and 96.0% ± 0.16%), through increasing induction of microbicide molecule NO. Additionally, ADMET-Tox in silico predictions showed drug-like features and free of toxicological risks. The molecular docking studies with arginase and gp63 showed that relevant intermolecular interactions could explain the experimental results. Therefore, these results reinforce that benzoylguanidines could be a starting scaffold for the search for new antileishmanial drugs. Graphical Abstract Communicated by Ramaswamy H. Sarma

3 November 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
GGGabriel Felix da Silva Gomes
Gabriel Felix da Silva Gomes
PCPriscila Goes Camargo
Priscila Goes Camargo
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
HSHelena Tiemi Suzukawa
Helena Tiemi Suzukawa
ARAna Paula Sotero da Silva Ribeiro
Ana Paula Sotero da Silva Ribeiro
CPCarla Cristina Perez
Carla Cristina Perez
COVID-19, a disease caused by SARS-CoV-2, was declared a pandemic in 2020 and created a global crisis in health systems, with more than 545 million confirmed cases and 6.33 million deaths. In this sense, this work aims to identify possible inhibitors of the SARS-CoV-2 RdRp enzyme using in silico approaches. RdRp is a crucial enzyme in the replication and assembly cycle of new viral particles and a critical pharmacological target in the treatment of COVID-19. We performed a virtual screening based on molecular docking from our in-house chemical library, which contains a diversity of 313 structures from different chemical classes. Nine compounds were selected since they showed important interactions with the active site from RdRp. Next, the ADME-Tox in silico predictions served as a filter and selected the three most promising compounds: a coumarin LMed-052, a hydantoin LMed-087, and a guanidine LMed-250. Molecular dynamics simulations revealed details such as changes in the positions of ligands and catalytic residues during the simulations compared to the complex from molecular docking studies. Binding free energy analysis was performed using the MMGBSA method, demonstrating that LMed-052 and LMed-087 have better affinities for the RdRp by energetic contributions to the stability of the complexes when compared to LMed-250. Furthermore, LMed-052 showed significant in vitro inhibition against MHV-3, decreasing 99% of viral titers. Finally, these findings are useful to guide structural modifications aiming to improve the potential of these compounds to act as inhibitors of SARS-CoV-2. Communicated by Ramaswamy H. Sarma

20 September 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
PCPriscila Goes Camargo
Priscila Goes Camargo
GGGabriel Felix da Silva Gomes
Gabriel Felix da Silva Gomes
ASAna Paula Sotero
Ana Paula Sotero
AOAlexandre Orsato
Alexandre Orsato
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
The coronavirus disease-2019 (COVID-19) pandemic, caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), became the highest public health crisis nowadays. Although the use of approved vaccines for emergency immunization and the reuse of FDA-approved drugs remains at the forefront, the search for new, more selective, and potent drug candidates from synthetic compounds is also a viable alternative to combat this viral disease. In this context, the present study employed a computational virtual screening approach based on molecular docking and molecular dynamics (MD) simulation to identify possible inhibitors for SARS-CoV-2 Mpro (main protease), an important molecular target required for the maturation of the various polyproteins involved in viral replication. The virtual screening approach selected four potential inhibitors against SARS-CoV-2 Mpro. In addition, MD simulation studies revealed changes in the positions of the ligands during the simulations compared to the complex obtained in the molecular docking studies, showing the benzoylguanidines LMed-110 and LMed-136 have a higher affinity for the active site compared to the other structures that tended to leave the active site. Besides, there was a better understanding of the formation and stability of the existing H-bonds in the formed complexes and the energetic contributions to the stability of the target-ligand molecular complexes. Finally, the in silico prediction of the ADME profile suggested that LMed-136 has drug-like characteristics and good pharmacokinetic properties. Therefore, from the present study, it can be suggested that these structures can inhibit SARS-CoV-2 Mpro. Nevertheless, further studies are needed in vitro assays to investigate the antiviral properties of these structures against SARS-CoV-2. Graphical Abstract Communicated by Ramaswamy H. Sarma

14 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
PCPriscila Goes Camargo
Priscila Goes Camargo
LCLarissa Esteves Carvalho Constant
Larissa Esteves Carvalho Constant
SCStephany da Silva Costa
Stephany da Silva Costa
GFGiovanna Barbosa Frensel
Giovanna Barbosa Frensel
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
Scientists and researchers have been searching for drugs targeting the main protease (Mpro) of SARS-CoV-2, which is crucial for virus replication. This study employed a virtual screening based on molecular docking to identify benzoylguanidines from an in-house chemical library that can inhibit Mpro on the active site and three allosteric sites. Molecular docking was performed on the LaSMMed Chemical Library using 88 benzoylguanidine compounds. Based on their RMSD values and conserved pose, three potential inhibitors (BZG1, BZG2, and BZG3) were selected. These results indicate that BZG1 and BZG3 may bind to the active site, while BZG2 may bind to allosteric sites. Molecular dynamics data suggest that BZG2 selectively targets allosteric site 3. In vitro tests were performed to measure the proteolytic activity of rMpro. The tests showed that BZG2 has uncompetitive inhibitory activity, with an IC50 value of 77 µM. These findings suggest that benzoylguanidines possess potential as Mpro inhibitors and pave the way towards combating SARS-Cov-2 effectively.